Compounded tirzepatide and compounded semaglutide have no set prices, but they are not FDA approved and are no longer allowed to be manufactured in the U.S
Very common side effects (affecting more than 1 in 10 people) include: Nausea often most pronounced when initiating treatment or increasing the dose Diarrhoea may be transient and typically improves with continued use Decreased appetite a therapeutic effect but may lead to inadequate nutrition if extreme Common side effects (affecting up to 1 in 10 people) include: Vomiting can contribute to dehydration if severe or persistent Constipation may occur as part of gastrointestinal effects Abdominal pain or discomfort usually mild and self-limiting Dyspepsia (indigestion) Fatigue may relate to reduced caloric intake or metabolic changes Injection site reactions redness, itching, or swelling at the injection site Hypoglycaemia particularly when Mounjaro is used in combination with insulin or sulfonylureas [1] [19] To minimise gastrointestinal side effects, the SmPC recommends starting at the lowest dose (2.5 mg weekly) and gradually titrating upwards every four weeks
Missing a scheduled dose may reduce therapeutic effects until dosing resumes, though the consequences depend largely on how long the dose is delayed
Summary: Ozempic (semaglutide) is not recognised as a direct cause of heavy menstrual bleeding, though metabolic changes from treatment may theoretically influence menstrual patterns
It was also noted that in comparison to a 1.2 mg dose of the active control, doses of semaglutide ranging from 0.8-1.6 resulted in a greater reduction in fasting plasma glucose
No formal washout period is required
